N/A N=11 Study Evaluating Liver Transplantation in Haemophilia Patients in Spain
Hemophilia · Hemophilia B
Primary: Number of Participants Requiring Immunosuppressive Therapy After Liver Transplantation — 7; 6; 4; 3 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=1,425 Post-Marketing Surveillance of Micombi Tablets Survey on the Long-term Use
Hypertension
Primary: Incidence of Adverse Events (AEs) — 221; 72; 293; 154 Patients
Phase 3 N=911 IMMEDIATE Trial - Out of Hospital Administration of Glucose, Insulin and Potassium.
Angina, Unstable · Cardiovascular Diseases · Heart Diseases
Primary: Progression of Acute Coronary Syndrome to Myocardial Infarction — 200; 242 participants — p=0.28
Phase 2 N=38 The Purpose of This Study is to Evaluate the Pharmacokinetic Properties of Intravitreal Ocriplasmin Prior to Planned Primary Pars Plana Vitrectomy (PPV)
Vitrectomy
Primary: Ocriplasmin Activity Levels in Vitreous Samples Obtained at the Beginning of Vitrectomy. — 11597.711; 8108.726; 2610.563; 496.473 ng/mL
Phase 2 N=264 Three Dose Levels of CP-690,550 Monotherapy Versus Placebo, Administered Orally Twice Daily (BID) for 6 Weeks
Rheumatoid Arthritis
Primary: Percentage of Participants Achieving American College of Rheumatology 20% (ACR20) Response at Week 6 — 70.49; 81.16; 76.81; 29.23 percentage of participants
N/A N=341 Drug Use Survey of RESPIMAT in Patients With COPD
Pulmonary Disease, Chronic Obstructive
Primary: Incidence of Adverse Events (AEs) — 53; 16 Patients
Phase 4 N=642 Counseling and Nicotine Replacement Therapy in Helping Adult Smokers Quit Smoking
Bladder Cancer · Cervical Cancer · Esophageal Cancer
Primary: 24-hour Point Prevalence Abstinence at the 6-month Follow up — 50; 35 participants — p=.05
N/A N=335 Clarithromycin Modified Release Observational Study for Evaluation of Treatment, Tolerability & Recovery Time in Saudi & Egyptian Clinical Settings (CLOSER)
Respiratory Tract Infection
Primary: Percentage of Participants With a Fast Recovery — 12.8; 54.3; 27.4; 29.7 percentage of participants
Phase 2 N=175 Treatment Interruption of Natalizumab
Relapsing Remitting Multiple Sclerosis
Primary: Time Course to Return of Radiological and/or Clinical Evidence of Multiple Sclerosis Activity, as Measured by the Percentage of Subjects Who Met Magnetic Resonance…
N/A N=156 Eliminating Risk of Preventable Adverse Drug Events at the Hospital-community Interface of Care
Adverse Drug Events
Primary: Health Services Utilization 3 Months Following Hospital Discharge — 3.33; 3.40 Health Services Utilizations — p=.87
Phase 2 N=37 Regimen for the Treatment of Cachexia in Subjects With NSCLC
Cachexia
Primary: Proportion of Subjects With a Positive Change From Baseline to Week 4 in Lean Body Mass — 8; 6; 5; 3 participants
Phase 2 N=125 A Study of the Safety and Efficacy of Microplasmin to Induce a Posterior Vitreous Detachment (MIVI III)
Vitrectomy
Primary: Proportion of Patients Achieving Total Posterior Vitreous Detachment (PVD) Without Creation of an Anatomical Defect — 13.8; 18.2; 31.3; 10 percentage of participants…
Phase 2 N=54 Trental & Vitamin E for Radiation-Induced Fibrosis
Fibrosis
Primary: Subjective, Objective, Management, and Analytic (SOMA) Score — 1.59; 1.0 units on a scale
Phase 4 N=30 Effect of Single Dose Intranasal Insulin On Cognitive Function
Schizophrenia · Schizoaffective Disorder
Primary: Improvement in Cognitive Function- HVLT Immediate Recall Total (Number) — 4.9; 5.3 Words successfully recalled
N/A N=86 Vanderbilt Pertussis Exposure Study: PEP in Vaccinated Healthcare Workers Following Pertussis Exposure
Pertussis
Primary: Evidence of Pertussis Infection in Each PEP Arm, Defined Using Clinical, Microbiologic, or Serologic Criteria. — 6; 1 participants